Nurse workload and inexperienced medical staff members are associated with seasonal peaks in severe adverse events in the adult medical intensive care unit: A seven-year prospective study

2016 ◽  
Vol 62 ◽  
pp. 60-70 ◽  
Author(s):  
Christophe Faisy ◽  
Cindy Davagnar ◽  
Dominique Ladiray ◽  
Juliette Djadi-Prat ◽  
Maxime Esvan ◽  
...  
Radiology ◽  
1996 ◽  
Vol 199 (1) ◽  
pp. 143-149 ◽  
Author(s):  
H L Kundel ◽  
S B Seshadri ◽  
C P Langlotz ◽  
P N Lanken ◽  
S C Horii ◽  
...  

2021 ◽  
pp. 106002802110533
Author(s):  
Lara M. Groetzinger ◽  
Julia Williams ◽  
Susan Svec ◽  
Michael P. Donahoe ◽  
Phillip E. Lamberty ◽  
...  

Background: Reducing central venous catheter (CVC) utilization can reduce complications in the intensive care unit (ICU). While norepinephrine (NE) is traditionally administered via a CVC, lower concentrations may be safely administered via peripheral intravenous (PIV) lines. Objective: We aimed to describe the implementation of a pilot protocol utilizing PIVs to administer a low-dose and lower-concentration NE, review the number of CVCs avoided, and evaluate any adverse events. Methods: In a quaternary medical intensive care unit (MICU), from March 1, 2019, to February 29, 2020, we reviewed charts for CVC placement and adverse events from the pNE infusion. We also measured unit-level CVC utilization in all MICU patients and assessed the change in utilization associated with the peripheral norepinephrine (pNE) protocol. Results: Over a 1-year period, 87 patients received a pNE infusion. Overall, 44 patients (51%) never required CVC placement during their MICU stay. Three patients (3%) experienced adverse events, none of which were documented as serious and or required antidote for treatment. Implementation of the protocol was associated with a decrease in the number of patients at the unit level who received CVCs, even if they did not receive pNE. Conclusion and Relevance: In this small pilot study, we pragmatically demonstrated that pNE is safe and may reduce the need for CVC placement. This information can be used to aid in pNE protocol development and implementation at other institutions, but further research should be done to confirm the safety of routine use of pNE in clinical practice.


2019 ◽  
Vol 26 (5) ◽  
pp. 1244-1247
Author(s):  
Jiyeon J Park ◽  
Esther Huang ◽  
Catherine A Monteleone ◽  
Michael P Kane ◽  
Dennis L Cooper

Introduction Pomalidomide is an immunomodulating agent that is used to treat relapsed and/or refractory multiple myeloma. Although the incidence of hypersensitivity with pomalidomide is not well documented, the most common type of hypersensitivity involves a cutaneous reaction. Previous reports have successfully utilized a desensitization protocol in patients who developed hypersensitivity to pomalidomide. Here we describe a case of a patient who developed urticaria on pomalidomide and successfully underwent a desensitization using the previously reported method in a case report. Case report A 68-year-old woman with relapsed multiple myeloma and no known drug allergies developed urticaria a day after taking the first dose of pomalidomide. Management and Outcome The patient underwent a 10-step desensitization process in the medical intensive care unit without any reported adverse events. The following day in the medical intensive care unit, the patient was able to tolerate a full dose of pomalidomide with no further reactions and was discharged with instructions to take a full dose of pomalidomide daily for 21 days out of a 28-day cycle. The patient was followed up in the outpatient clinic and noted no further reactions from pomalidomide at the three-month visit. Discussion The 10-step desensitization protocol with pomalidomide was well tolerated in the patient with hypersensitivity to pomalidomide. Whether this approach would work in patients with more severe reactions such as anaphylaxis and angioedema is still unknown.


Sign in / Sign up

Export Citation Format

Share Document